Benign Prostatic Hypertrophy Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms(LUTS) Due to Benign Prostatic Hypertrophy (BPH)
This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy (BPH) who are over 50 years of age.
This study is to compare the improvement in symptom scores, peak flow rate and quality of life in men suffering from lower urinary tract symptoms (LUTS) secondary to Benign Prostatic Hypertrophy (BPH) following treatment with ozarelix. Ozarelix is compared to placebo and injections given 14 days apart. Patients are followed for 6 months and both safety and efficacy assessed at monthly visits. Additionally, the impact of treatment on erectile function, if any, as well as Prostate-Specific Antigen (PSA) and Testosterone levels will be monitored. The screening period of 7 days. The duration of the study is 40 weeks, including a 28-day placebo run-in phase (eligible participants entered a placebo run-in phase in which placebo is administered twice over a 2 week period [Day -28 and Day -14] and participants are assessed to establish baseline values approximately 14 days following the second placebo injection), study drug is administered on Days 0 and 14 followed by 34 weeks of observation after the last dose of study drug. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02509975 -
Safety and Efficacy of OCL 503 in Prostate Artery Embolization
|
N/A | |
Completed |
NCT01177436 -
Prostate Cancer Antigen 3 (PCA-3) Gene Project
|
N/A | |
Completed |
NCT05082142 -
Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)
|
Phase 4 | |
Completed |
NCT01260129 -
Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH
|
Phase 4 | |
Completed |
NCT00771394 -
Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia
|
Phase 4 | |
Active, not recruiting |
NCT03630926 -
Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.
|
||
Completed |
NCT02429219 -
Saline With Alcohol in TransUrethral Resection aNd Photoselective Vaporisation of the Prostate
|
N/A | |
Completed |
NCT01342562 -
The Effects of Intrathecal Dexmedetomidine on Spinal Anesthesia Using Diluted Low-Dose Bupivacaine for Transurethral Resection of Prostate in Elderly
|
N/A | |
Completed |
NCT00382356 -
Dutasteride After Failure of Finasteride In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H)
|
N/A | |
Completed |
NCT00029822 -
Clinical Trial in Males With BPH (Enlarged Prostate)
|
Phase 3 | |
Completed |
NCT05308017 -
Wolf 24 F vs. Storz 28 F Laser Sheath Size for HoLEP
|
N/A | |
Completed |
NCT00663858 -
Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
|
Phase 3 | |
Completed |
NCT00670306 -
Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
Terminated |
NCT00449150 -
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
|
Phase 3 | |
Completed |
NCT00037141 -
Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)
|
Phase 1/Phase 2 | |
Suspended |
NCT02533687 -
Comparison of Different Energy Sources During TUR-P
|
N/A | |
Completed |
NCT04781049 -
Transperineal Laser Ablation vs Transurethral Resection for Benign Prostatic Obstruction: A Randomized Clinical Trial
|
N/A | |
Completed |
NCT02051036 -
Moxibustion as an Adjuvant for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms: a Pilot Study
|
N/A | |
Completed |
NCT00634608 -
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
|
N/A | |
Completed |
NCT02401581 -
Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours
|
N/A |